Long-term maintenance

Weight regain after stopping GLP-1 treatment: what trials found

Weight regain was common after semaglutide or tirzepatide withdrawal in clinical studies. The studies used different designs and their averages cannot predict an individual result.

Editorial analysis · Not a clinical consultation

In this article

What happened after semaglutide stopped

The STEP 1 extension followed 327 participants for one year after the original trial ended. Participants previously assigned injectable semaglutide had lost an average of 17.3% of their starting weight by week 68. They regained 11.6 percentage points by week 120 and remained an average of 5.6% below their starting weight. Trials of structured weight maintenance ask what happens when people receive different kinds of ongoing support. In the STEP 1 extension, both the medication and structured lifestyle intervention ended, so the study cannot isolate what would happen if that support continued. [1]

What a randomized withdrawal trial adds

SURMOUNT-4 assigned 670 adults who completed an initial 36 weeks of tirzepatide to continue treatment or switch to placebo. Over the next 52 weeks, the continuation group lost another 5.5% on average and the switch group gained 14.0%, measured from the time of the switch. The trial excluded diabetes and selected people who completed the lead-in, so the results do not describe everyone who starts a prescription. [2]

What the two studies can tell you

A 14% gain measured from the point of withdrawal and the fraction of earlier weight loss regained describe different things. Neither study establishes which drug is more likely to lead to regain after stopping, how much a given person will regain, or whether a specific stopping schedule will prevent it. The evidence supports discussing maintenance support before treatment changes. [1] [2]

Questions to raise before a treatment change

Ask the prescribing clinician how follow-up will work if cost, side effects or supply interrupt treatment. A weight trend worksheet can help you describe changes over several weeks if weighing is appropriate for you. It cannot determine what caused a change. Discuss which measurements, symptoms or concerns should prompt a follow-up and who will review them.

Sources

  1. STEP 1 extension: weight and cardiometabolic outcomes after semaglutide withdrawal (opens in a new tab)
  2. SURMOUNT-4 randomized tirzepatide withdrawal trial (opens in a new tab)

Research describes groups and specific study conditions. Your medical history, symptoms and treatment decisions require advice from your own qualified clinician.

Keep exploring.

Research library
Affiliate partner

Before you go

Explore this option
Continue to your original choiceWe may earn a commission if you choose our partner. These services may differ in products, fees and clinical access.